Both monotherapies led to TRAMP-C1 tumor volume reduction (cyto-IL-15 by 63% and ADU by 84%) and increased survival (cyto-IL-15 to 41 and ADU to 45 days) compared with HBSS by day 28 post-treatment, which was the survival endpoint for the HBSS treated tumors (Figures 1A–D). This evidence concerns the gene IL15 and neoplasm.